secretagogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-17. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Solubility | Freely soluble in water and polar solvents | Dissolution may require brief mixing |
| Typical storage temperature | Minus 20 degrees Celsius or below | Dry, desiccated, protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Purity plus identity confirmation |
| Common synonyms | Ipamorelin acetate, NNC 26-0161 | Research code used in early literature |
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
== V == Valine Valinomycin Vanabins Vasopressin Verruculogen Vitamins (in general) Vitamin A (retinol) Vitamin B Vitamin B1 (thiamine) Vitamin B2 (riboflavin) Vitamin B3 (niacin or nicotinic acid) Vitamin B4 (adenine) Vitamin B5 (pantothenic acid) Vitamin B6 (pyridoxine or pyridoxamine) Vitamin B12 (cobalamin) Vitamin C (ascorbic acid) Vitamin D (calciferol) Vitamin E (tocopherol) Vitamin F Vitamin H (biotin) Vitamin K (naphthoquinone) Vitamin M (folic acid)
== Properties of the interface == The study of the molecular structure can give fine details about the interface that enables the interaction between proteins. When characterizing PPI interfaces it is important to take into account the type of complex. Parameters evaluated include size (measured in absolute dimensions Å2 or in solvent-accessible surface area (SASA)), shape, complementarity between surfaces, residue interface propensities, hydrophobicity, segmentation and secondary structure, and conformational changes on complex formation. The great majority of PPI interfaces reflects the composition of protein surfaces, rather than the protein cores, in spite of being frequently enriched in hydrophobic residues, particularly in aromatic residues. PPI interfaces are dynamic and frequently planar, although they can be globular and protruding as well. Based on three structures – insulin dimer, trypsin-pancreatic trypsin inhibitor complex, and oxyhaemoglobin – Cyrus Chothia and Joel Janin found that between 1,130 and 1,720 Å2 of surface area was removed from contact with water indicating that hydrophobicity is a major factor of stabilization of PPIs. Later studies refined the buried surface area of the majority of interactions to 1,600±350 Å2. However, much larger interaction interfaces were also observed and were associated with significant changes in conformation of one of the interaction partners. PPIs interfaces exhibit both shape and electrostatic complementarity.
Hydrophobicity scales are values that define the relative hydrophobicity or hydrophilicity of amino acid residues. The more positive the value, the more hydrophobic are the amino acids located in that region of the protein. These scales are commonly used to predict the transmembrane alpha-helices of membrane proteins. When consecutively measuring amino acids of a protein, changes in value indicate attraction of specific protein regions towards the hydrophobic region inside lipid bilayer. The hydrophobic or hydrophilic character of a compound or amino acid is its hydropathic character, hydropathicity, or hydropathy.
Sources: en.wikipedia.org
=== We–Wh === Edwin C. Webb (1921–2006). British (later Australian) biochemist at the University of Queensland and Macquarie University. Editor of Enzyme Nomenclature until 1992. Gregorio Weber (1916–1997). Argentinian spectroscopist at the University of Illinois, who pioneered the application of fluorescence spectroscopy to the biological sciences. Member Natl. Acad. Sci. USA, National Academy of Sciences of Argentina. Stephen C. West FRS (b. 1952). British biochemist at the Francis Crick Institute, London, known for his work on DNA recombination and repair. Foreign Associate Natl. Acad. Sci. USA. Hans Westerhoff (b. 1953). Dutch biochemist at the Universities of Amsterdam and of Manchester, known for work in systems biology and metabolic regulation. Frank Henry Westheimer (1912–2007). American chemist at Harvard who did pioneering work in physical organic chemistry, applying techniques from physical to organic chemistry and integrating the two fields. Member Natl. Acad. Sci. USA. John Westley (b. 1927). American enzymologist at the University of Chicago known for work on rhodanese and sulfurtransferases in general. Frederick Whatley (1924–2020). British botanist and biochemist at the University of Sydney known for work on photosynthesis. William Joseph Whelan FRS (1924–2021). British-American biochemist at the University of Miami, who worked on the structure of glycogen, and discovered the protein glycogenin at its core. He was very active in the creation of international organizations, including the IUB (now IUBMB) and FEBS.
A material-dependent unit used in nuclear and particle physics and engineering to measure the thickness of shielding, for example around a nuclear reactor, particle accelerator, or radiation or particle detector. 1 mwe of a material is the thickness of that material that provides the equivalent shielding of one metre (≈39.4 in) of water. This unit is commonly used in underground science to express the extent to which the overburden (usually rock) shields an underground space or laboratory from cosmic rays. The actual thickness of overburden through which cosmic rays must traverse to reach the underground space varies as a function of direction due to the shape of the overburden, which may be a mountain, or a flat plain, or something more complex like a cliff side. To express the depth of an underground space in mwe (or kmwe for deep sites) as a single number, the convention is to use the depth beneath a flat overburden at sea level that gives the same overall cosmic ray muon flux in the underground location.
==== United States ==== The combination was approved for use in the United States in 2019, for people twelve years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis population. In December 2020, after an additional clinical trial was completed, and FDA approval was expanded for 177 other cystic fibrosis mutations. FDA approval for children aged 6–11 was added in January 2021, after a third clinical trial was completed. In 2023, approval was extended to children 2–5. The US Food and Drug Administration (FDA) granted the application priority review, in addition to fast track, breakthrough therapy, and orphan drug designations. The drug's manufacturer Vertex Pharmaceuticals will receive a rare pediatric disease priority review voucher for having developed this therapy.
Sources: en.wikipedia.org
=== Nuclear activism === The aftermath of the Manhattan Project and his wife Ava's pacifism changed Pauling's life profoundly, and he became a peace activist. In June 1945, a "May-Johnson Bill" began that would become the Atomic Energy Act of 1946 (signed August 1, 1946). In November 1945, Pauling spoke to the Independent Citizens Committee of the Arts, Sciences and Professions (ICCASP) on atomic weapons; shortly after, wife Ava and he accepted membership. On January 21, 1946, the group met to discuss academic freedom, during which Pauling said, "There is, of course, always a threat to academic freedom – as there is to the other aspects of the freedom and rights of the individual, in the continued attacks which are made on this freedom, these rights, by the selfish, the overly ambitious, the misguided, the unscrupulous, who seek to oppress the great body of mankind in order that they themselves may profit – and we must always be on the alert against this threat, and must fight it with vigor when it becomes dangerous." In 1946, he joined the Emergency Committee of Atomic Scientists, chaired by Albert Einstein. Its mission was to warn the public of the dangers associated with the development of nuclear weapons.
Bush authorized the CIA to use waterboarding and several other "enhanced interrogation techniques" that several critics, including Barack Obama, would label as torture. Between 2002 and 2003, the CIA considered certain enhanced interrogation techniques, such as waterboarding, to be legal based on secret Justice Department legal opinions arguing that terror detainees were not protected by the Geneva Conventions' ban on torture, which was described as "an unconstitutional infringement of the President's authority to conduct war". The CIA had exercised the technique on certain key terrorist suspects under authority given to it in the Bybee Memo from the Attorney General, though the memo was later withdrawn. While not permitted by the U.S. Army Field Manuals which assert "that harsh interrogation tactics elicit unreliable information", the Bush administration believed these enhanced interrogations "provided critical information" to preserve American lives. Critics, such as former CIA officer Bob Baer, have stated that information was suspect, "you can get anyone to confess to anything if the torture's bad enough." On October 17, 2006, Bush signed the Military Commissions Act of 2006 into law. The new rule was enacted in the wake of the Supreme Court's decision in Hamdan v. Rumsfeld, 548 U.S. 557 (2006), which allowed the U.S. government to prosecute unlawful enemy combatants by military commission rather than a standard trial. The law also denied the detainees access to habeas corpus and barred the torture of prisoners.
=== Photo-chemically and electro-chemically active units === Porphyrins, and phthalocyanines have highly tunable photochemical and electrochemical activity as well as the potential to form complexes. Photochromic and photoisomerizable groups can change their shapes and properties, including binding properties, upon exposure to light. Tetrathiafulvalene (TTF) and quinones have multiple stable oxidation states, and therefore can be used in redox reactions and electrochemistry. Other units, such as benzidine derivatives, viologens, and fullerenes, are useful in supramolecular electrochemical devices.
== Academic career == Beynon took a position as Professor of Chemistry and Director of the Mass Spectrometry Center at Purdue University in 1968. In 1974 Beynon accepted a position as Royal Society Research Professor and Director of the Mass Spectrometry Research Unit at Swansea University.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.
The peptide contains aromatic and imidazole groups that absorb ultraviolet light and can participate in photo-induced reactions. Those reactions can alter the molecule or generate new species. Amber glass or opaque packaging reduces the exposure.
Long-term stability data across many temperature and humidity conditions are limited. Most guidance is extrapolated from short studies on related peptides. The effect of repeated handling on a specific lot is generally not characterized.
Typical guidance is -20 °C in a sealed container with desiccant and protection from light. The powder tolerates handling better than a solution, but repeated warming and cooling is still avoided.